Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT06946914
Recruiting Phase 4

Misoprostol Before Caesarean Section

NCT06946914 · tracked via the Priya Life Science Egypt tracker
Sponsor
Kafrelsheikh University
Phase
Phase 4
Started
2024-06-01
Last updated
2025-05-13

Condition(s) studied

MisoprostolRespiratory Distress Syndrome (RDS) of NeonateCaesarean Section

Investigational drug(s) / intervention(s)

Misoprostol →

Misoprostol: administration of 100mg of misoprostol to evaluate the efficacy of Misoprostol before elective cesarean section in pregnant women with gestational age less than 38 weeks for preventing the occurrence of neonatal respiratory morbidity.

Study summary

The aim of our study is to evaluate the efficacy of Misoprostol before elective cesarean section in pregnant women with gestational age less than 38 weeks for preventing the occurrence of neonatal respiratory morbidity.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Women with indication for elective caesarean section. * Age less than 35 years old. * Gestational age less than 38 weeks. * Gestational age will be confirmed by certain LMP or reliable early ultrasound measurement of crown-rump length. * Singleton pregnancy with no major anomalies Exclusion Criteria: * Any obstetric disorders as preeclampsia and diabetes. * Fetus with oligohydramnios, intrauterine growth restriction. * Any contraindications to misoprostol like those with previous allergic reaction or hypersensitivity to prostaglandin hemorrhagic disorders, and severe anemia. * History of more than or equal 2 previous caesarean section.

Primary outcome measure(s)

  • the incidence of Transient tachypnea of the newborn which defined by increase respiratory rate more than 60 cycle per minute in pregnant women with gestational age less than 38 weeks before elective cesarean section — in the first 5 minute after delivery of fetus post operative

Trial sites (1)

FacilityCityRegionStatus
Kafr El-sheikh University Hospital Kafr Ash Shaykh, Egypt Egypt Recruiting

More Kafrelsheikh University trials in Egypt

Effect of Task Specific Electrical Stimulation on Upper Limb Gross Motor Skills in Children With Spastic Quadriplegia Recruiting
Affection of Symptoms Duration on Outcomes of Lumbar Spine Surgery Recruiting
Bone Cement Augmented Transpedicular Screw Fixation Versus Cannulated Screws Fixation in Osteoporotic Spine Recruiting
Evaluation of Internal Nasal Splint-Supported Free Graft Versus Nasoseptal Flap for Endoscopic Skull Base Repair in Cerebrospinal Fluid Leaks Recruiting
No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06946914 on ClinicalTrials.gov ↗ ← All trials in Egypt